Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial

Completed · Phase 2 · Has a placebo group

Conditions studied: Substance Abuse

In brief

This placebo-controlled, double-blind, randomized pilot clinical trial will evaluate atomoxetine (Strattera®) for the treatment of cocaine dependence. Cocaine-dependent individuals, who are healthy and are seeking treatment for their substance abuse, will be randomized to receive either atomoxetine (n=25) or a matched-placebo (n=25) during a trial lasting 12 weeks; there will be a double-blind, ascending dose lead-in order to achieve maintenance on the assigned active dose safely. Contingency management procedures will be used to reinforce attendance and compliance with study procedures. Primary outcome measures will include urinalysis data assessing cocaine use.

Key facts

Study ID

NCT00617201

Run by

Sharon Walsh

People needed

50

Starts

2007-07-01

Expected to finish

2011-08-01

Last updated by the study team

2017-08-31

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Seeking treatment for cocaine dependence
• Must have used cocaine in the past 30 days

You may not qualify if…

• Physical dependence on any drug requiring medical management
• Any major medical or psychiatric disorder that would be contraindicated for participation
• Cardiovascular disease
• Seizures or significant head injuries
• Currently taking atomoxetine
• Pregnant or breast-feeding

Where it is running

• Straus Research Building — Lexington, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.